Effect of different dose options of continuous combined hormone therapy on bone and bone marker N-terminal propeptide of type I procollagen: Results from a long-term study in Finnish postmenopausal women

Postmenopausal Osteoporosis: Hormones and Other Therapies

Volumn , Issue , 2016, Pages 281-288

  Heikkinen, J ^a   Haapalahti, J ^b  

^a OULU DEACONESS INSTITUTE   (Finland)

^b Orion Diagnostica Oy   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 67650475342     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (4)

1. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative randomized controlled trial. J Am Med Assoc 2002; 228: 321-33
2. North American Menopause Society. Estrogen and progestogen use in peri-and postmenopausal women: September 2003 position statement of the North American Menopause Society. Menopause 2003; 10: 497-506
3. Heikkinen J, Vaheri R, Kainulainen P, et al. Longterm continuous combined hormone replacement therapy in the prevention of postmenopausal bone loss: a comparison of high-and low-dose estrogen-progestin regimens. Osteoporos Int 2000; 11: 929-37
4. Heikkinen J, Vaheri R, Timonen U. Long-term safety and tolerability of continuous-combined hormone therapy in postmenopausal women: results from a seven-year randomized comparison of low and standard doses. J Br Menopause Soc 2004; 10: 95-102